Ehsani Laleh, Osunkoya Adeboye O
Department of Pathology, Emory University School of Medicine Atlanta, GA, USA.
Department of Pathology, Emory University School of Medicine Atlanta, GA, USA ; Department of Urology, Emory University School of Medicine Atlanta, GA, USA ; Emory Winship Cancer Institute Atlanta, GA, USA.
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2544-50. eCollection 2014.
The significance of human epidermal growth factor receptor 2 (HER2) overexpression in breast cancer is well established, and these patients are subsequently treated with Trastuzumab. Although HER2 expression in urothelial carcinoma of the urinary bladder has also been recently characterized, it has not been well studied in urothelial carcinoma of the renal pelvis. We investigated the relationship between HER2 overexpression in urothelial carcinoma of the renal pelvis and clinicopathologic parameters. Forty six cases were identified. HER2 overexpression was present in 34/46 (74%) cases. Mean patient age with HER2 overexpression was 68 years (range: 42-87 years). There was a male predominance with 28/34 (82%) patients. High grade urothelial carcinoma was present in 32/34 (94%) cases and 2/34 (6%) cases had low grade urothelial carcinoma. Pathologic staging was as follows; 9/34 (26%) cases were pTa, 10/34 (29%) cases were pT1, 2/34 (6%) cases were pT2, 12/34 (35%) cases were pT3, and 1/34 (3%) cases was pT4. An inverted growth pattern was present in 23/46 (50%) cases. HER2 overexpression was present in 15/23 (65%) cases of urothelial carcinoma with an inverted growth pattern. Our study showed that HER2 overexpression is more common in male patients with high grade urothelial carcinoma, especially those with an inverted growth pattern. It is highly conceivable that patients with urothelial carcinoma of the renal pelvis may be further stratified based on HER2 overexpression, and may also be potential candidates for Trastuzumab therapy in the neoadjuvant or adjuvant setting.
人表皮生长因子受体2（HER2）在乳腺癌中过表达的意义已得到充分证实，这些患者随后接受曲妥珠单抗治疗。尽管膀胱尿路上皮癌中HER2的表达最近也已得到表征，但在肾盂尿路上皮癌中尚未得到充分研究。我们研究了肾盂尿路上皮癌中HER2过表达与临床病理参数之间的关系。共确定了46例病例。46例中有34例（74%）存在HER2过表达。HER2过表达患者的平均年龄为68岁（范围：42 - 87岁）。男性占优势，28/34例（82%）为男性。34例中有32例（94%）为高级别尿路上皮癌，2例（6%）为低级别尿路上皮癌。病理分期如下：9/34例（26%）为pTa，10/34例（29%）为pT1，2/34例（6%）为pT2，12/34例（35%）为pT3，1/34例（3%）为pT4。46例中有23例（50%）呈现倒置生长模式。23例呈现倒置生长模式的尿路上皮癌中有15例（65%）存在HER2过表达。我们的研究表明，HER2过表达在患有高级别尿路上皮癌的男性患者中更为常见，尤其是那些具有倒置生长模式的患者。高度可以想象，肾盂尿路上皮癌患者可能会根据HER2过表达进一步分层，并且在新辅助或辅助治疗中也可能是曲妥珠单抗治疗的潜在候选者。
